Clinical Trials Browser

NIH × Interventional × pomalidomide × Clear all

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT07463807 2026-03-18

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT04902443 2026-03-13

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

Phase 1 Recruiting

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT02659930 2026-02-19

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Phase 1 Active not recruiting

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Phase 1 Recruiting

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Phase 2 Active not recruiting

50 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT01495598 2022-11-01

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

Phase 1/2 Completed

28 enrolled 23 charts

Sarcoma, Kaposi

NCT02415153 2022-04-25

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Phase 1 Completed

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

Phase 1/2 Withdrawn

Lymphoma, Primary Effusion